Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/NTRK2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NTRK2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NTRK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NTRK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NTRK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NTRK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NTRK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NTRK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0043010 | Oral cavity | NEOLP | camera-type eye development | 55/2005 | 322/18723 | 3.20e-04 | 3.11e-03 | 55 |
GO:007099732 | Oral cavity | NEOLP | neuron death | 60/2005 | 361/18723 | 3.70e-04 | 3.50e-03 | 60 |
GO:007123012 | Oral cavity | NEOLP | cellular response to amino acid stimulus | 18/2005 | 71/18723 | 3.79e-04 | 3.57e-03 | 18 |
GO:00182122 | Oral cavity | NEOLP | peptidyl-tyrosine modification | 62/2005 | 378/18723 | 4.27e-04 | 3.91e-03 | 62 |
GO:00017643 | Oral cavity | NEOLP | neuron migration | 31/2005 | 156/18723 | 4.96e-04 | 4.40e-03 | 31 |
GO:00181082 | Oral cavity | NEOLP | peptidyl-tyrosine phosphorylation | 61/2005 | 375/18723 | 5.88e-04 | 5.08e-03 | 61 |
GO:005196212 | Oral cavity | NEOLP | positive regulation of nervous system development | 47/2005 | 272/18723 | 6.49e-04 | 5.47e-03 | 47 |
GO:00331382 | Oral cavity | NEOLP | positive regulation of peptidyl-serine phosphorylation | 23/2005 | 108/18723 | 9.48e-04 | 7.33e-03 | 23 |
GO:199009022 | Oral cavity | NEOLP | cellular response to nerve growth factor stimulus | 14/2005 | 53/18723 | 1.06e-03 | 8.06e-03 | 14 |
GO:004320021 | Oral cavity | NEOLP | response to amino acid | 24/2005 | 116/18723 | 1.14e-03 | 8.51e-03 | 24 |
GO:20008111 | Oral cavity | NEOLP | negative regulation of anoikis | 7/2005 | 17/18723 | 1.18e-03 | 8.72e-03 | 7 |
GO:190121431 | Oral cavity | NEOLP | regulation of neuron death | 52/2005 | 319/18723 | 1.37e-03 | 9.77e-03 | 52 |
GO:005196012 | Oral cavity | NEOLP | regulation of nervous system development | 68/2005 | 443/18723 | 1.46e-03 | 1.03e-02 | 68 |
GO:005077221 | Oral cavity | NEOLP | positive regulation of axonogenesis | 18/2005 | 79/18723 | 1.46e-03 | 1.03e-02 | 18 |
GO:00015705 | Oral cavity | NEOLP | vasculogenesis | 18/2005 | 80/18723 | 1.70e-03 | 1.18e-02 | 18 |
GO:199008923 | Oral cavity | NEOLP | response to nerve growth factor | 14/2005 | 56/18723 | 1.89e-03 | 1.28e-02 | 14 |
GO:00219532 | Oral cavity | NEOLP | central nervous system neuron differentiation | 30/2005 | 162/18723 | 1.96e-03 | 1.32e-02 | 30 |
GO:00429822 | Oral cavity | NEOLP | amyloid precursor protein metabolic process | 20/2005 | 95/18723 | 2.28e-03 | 1.47e-02 | 20 |
GO:003367423 | Oral cavity | NEOLP | positive regulation of kinase activity | 70/2005 | 467/18723 | 2.33e-03 | 1.50e-02 | 70 |
GO:190121531 | Oral cavity | NEOLP | negative regulation of neuron death | 36/2005 | 208/18723 | 2.54e-03 | 1.60e-02 | 36 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0472214 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0472215 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa04722111 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0472220 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa04722110 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0472224 | Oral cavity | LP | Neurotrophin signaling pathway | 46/2418 | 119/8465 | 1.07e-02 | 3.77e-02 | 2.43e-02 | 46 |
hsa0472234 | Oral cavity | LP | Neurotrophin signaling pathway | 46/2418 | 119/8465 | 1.07e-02 | 3.77e-02 | 2.43e-02 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NTRK2 | SNV | Missense_Mutation | rs144037140 | c.407G>A | p.Arg136His | p.R136H | Q16620 | protein_coding | tolerated(0.41) | benign(0.007) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
NTRK2 | SNV | Missense_Mutation | rs200996090 | c.1156N>A | p.Asp386Asn | p.D386N | Q16620 | protein_coding | tolerated(0.75) | benign(0.001) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NTRK2 | SNV | Missense_Mutation | novel | c.1869N>G | p.Cys623Trp | p.C623W | Q16620 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NTRK2 | SNV | Missense_Mutation | rs778391314 | c.157N>A | p.Val53Met | p.V53M | Q16620 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NTRK2 | SNV | Missense_Mutation | novel | c.2324N>G | p.Asn775Ser | p.N775S | Q16620 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
NTRK2 | SNV | Missense_Mutation | | c.724N>A | p.Glu242Lys | p.E242K | Q16620 | protein_coding | tolerated(0.76) | benign(0.012) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NTRK2 | SNV | Missense_Mutation | | c.1318N>A | p.Ala440Thr | p.A440T | Q16620 | protein_coding | deleterious(0.02) | probably_damaging(0.983) | TCGA-E2-A1LS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cyclophosphamide | SD |
NTRK2 | SNV | Missense_Mutation | | c.167N>T | p.Pro56Leu | p.P56L | Q16620 | protein_coding | tolerated(0.1) | probably_damaging(1) | TCGA-E9-A22D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
NTRK2 | insertion | In_Frame_Ins | novel | c.2322_2323insGGCATACTGTGT | p.Ser774_Asn775insGlyIleLeuCys | p.S774_N775insGILC | Q16620 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
NTRK2 | deletion | Frame_Shift_Del | novel | c.50delG | p.Gly17AlafsTer47 | p.G17Afs*47 | Q16620 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | Macrocycle derivative 13 | | |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 249565751 | | |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 249565869 | CEP-11981 | |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | lithium | LITHIUM | 21047205,24885933 |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 381744997 | REPOTRECTINIB | |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PILOCARPINE | PILOCARPINE | 15183516 |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | AST-487 | AST-487 | |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL3545179 | AZD-7451 | |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 223366033 | | |
4915 | NTRK2 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | TCMDC-125758 | CHEMBL546797 | |